WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that management will participate in a fireside chat at the Jefferies Global Healthcare Conference in London on Wednesday, November 19, 2025 at 4:30 pm GMT/11:30 am ET. To access the live webcast of the panel presentation please visit the Events a ...

Gamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of providing actionable trading ideas and well-researched investment recommendations. His insights have been featured in reputable publications such as The Axis business magazine and Investment Quarterly ...

Gamu Dave Innocent Pasi is a seasoned financial professional and writer, bringing a wealth of experience from his prior roles as a financial analyst and in investment research. With a strong background in analyzing financial statements, capital markets, and the macro-economy, Gamu has a proven track record of providing actionable trading ideas and well-researched investment recommendations. His insights have been featured in reputable publications such as The Axis business magazine and Investment Quarterly ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .I am circling back on biopharma name, Ardelyx, Inc. ( ARDX ) in today's column. I last looked at Ardelyx in late December after the stock had suffered a reversal. I concluded that the articleBret Jensen has over 13 years as a market ana ...

WALTHAM, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that President and CEO, Mike Raab will participate in a fireside chat at the Wedbush Rewind ASN 2025 Conference on Monday, November 10, 2025 from 11:30 a.m. to 12:00 p.m. ET. To access the public webcast of the event, please visit the Events and ...

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

For the quarter ended September 2025, Ardelyx (ARDX) reported revenue of $110.33 million, up 12.3% over the same period last year. EPS came in at $0, compared to $0 in the year-ago quarter.The reported revenue represents a surprise of +10.52% over the Zacks Consensus Estimate of $99.83 million. With the consensus EPS estimate being -$0.06, the EPS surprise was +100%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expecta ...

Ardelyx (NasdaqGM:ARDX) Q3 2025 Earnings Call October 30, 2025 04:30 PM ET Speaker4Good day, everyone, and welcome to the Ardelyx Q3 2025 earnings conference call. All participants are in a listen-only mode. Now I'd like to turn the call over to Caitlin Lowie, Vice President of Corporate Communications and Investor Relations. Caitlin, please go ahead.Speaker3Thank you. Good afternoon and welcome to our Q3 2025 financial results call. During this call, we will refer to the press release issued earlier today, ...

总营收表现 - 2025年第三季度公司总营收为1.103亿美元，同比增长12%[87] - 2025年前九个月总营收为2.821亿美元，同比增长30%[87] IBSRELA药品净销售额 - 2025年第三季度IBSRELA药品净销售额为7816万美元，同比增长92%[87] - 2025年前九个月IBSRELA药品净销售额为1.876亿美元，同比增长80%[87] XPHOZAH药品净销售额 - 2025年第三季度XPHOZAH药品净销售额为2736万美元，同比下降47%[87] - 2025年前九个月XPHOZAH药品净销售额为7580万美元，同比下降27%[87] 合作协议与特许权收入 - 2025年第一季度因中国批准tenapanor新药申请，公司获得复星协议项下500万美元里程碑付款[80][93] - 截至2025年第二季度，公司已全额确认并支付阿斯利康终止协议项下7500万美元的特许权使用费义务[81] - 2025年第三季度非现金特许权收入为479万美元，同比增长492%，其中包含与Kyowa Kirin协议相关的约340万美元商业化里程碑付款[87][95] 成本和费用 - 总营业收入成本在2025年第三季度为398.2万美元，同比下降1174.6万美元（75%），九个月期间为2868.8万美元，同比下降360.4万美元（11%）[98] - 研发费用在2025年第三季度为1806.7万美元，同比增长275.7万美元（18%），九个月期间为4867.1万美元，同比增长1002万美元（26%）[98][102] - 销售、一般和行政费用在2025年第三季度为8361.2万美元，同比增长1864.2万美元（29%），九个月期间为25082.2万美元，同比增长6820.4万美元（37%）[98][104] - 与阿斯利康终止协议相关的其他收入成本在2025年第三季度为零，2024年同期为1000万美元；九个月期间为1270万美元，2024年同期为2270万美元[101] 利息费用 - 利息费用在2025年第三季度为579.6万美元，同比增长243.9万美元（73%），九个月期间为1434.3万美元，同比增长530.4万美元（59%）[98][105] 现金流与流动资金 - 公司现金及现金等价物在2025年9月30日为4271.5万美元，较2024年12月31日的6493.2万美元减少2221.7万美元（34%）[108] - 总流动资金（现金及现金等价物加短期投资）在2025年9月30日为2.427亿美元，较2024年12月31日的2.501亿美元减少739.5万美元（3%）[108] - 2025年前九个月经营活动所用现金净额为6343.4万美元，同比增加881.5万美元（16%）[113][114] - 截至2025年9月30日，公司现金、现金等价物和短期投资总额为2.427亿美元[118] 融资活动 - 根据2022年贷款协议，公司总贷款额度为3亿美元，截至2025年9月30日已提取2亿美元，其中5000万美元的E定期贷款于2025年第二季度提取[110] - 截至2025年9月30日，公司根据2023年公开市场销售协议已完成1680万股普通股的销售，获得总收入7000万美元，加权平均售价约为4.17美元[109] 财务风险 - 公司短期投资组合面临利率风险，但市场利率10%的变动不会对投资组合总价值产生重大影响[118] - 公司2022年贷款协议项下未偿还本金总额为2亿美元[119] - 2022年贷款协议利率变动风险：一个月期CME Term SOFR利率上升100个基点，将使公司在截至2025年9月30日的九个月内利息支出增加约130万美元[119] - 公司面临因瑞士法郎、日元和欧元交易产生的外汇风险[120] - 截至2025年9月30日，公司未持有任何未平仓远期外汇合约[121] 其他财务指标 - 2025年第三季度GTN（总至净额）调整百分比为30.6%，同比上升6.2个百分点，主要由于XPHOZAH失去医疗保险D部分报销导致支付方结构变化[96]

Exhibit 99.1 Q3 2025 product revenue of $105.5 million reflects 15% year-over-year growth IBSRELA Q3 revenue of $78.2 million reflects 92% year-over-year growth; IBSRELA guidance raised, 2025 revenue expected to be between $270-275 million ® Ardelyx Reports Third Quarter 2025 Financial Results and Provides Corporate Update XPHOZAH Q3 revenue of $27.4 million, up 9% compared to Q2 2025 ® Company announces pipeline program for next-generation NHE3 inhibitor; Potential application across multiple therapeutic a ...